Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05418101
Other study ID # VIS171-101
Secondary ID 2021-006246-12
Status Terminated
Phase Phase 1
First received
Last updated
Start date April 28, 2022
Est. completion date February 15, 2024

Study information

Verified date April 2024
Source Visterra, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1 study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of VIS171 in healthy participants and in participants with autoimmune disease(s).


Description:

This is a multicenter, 2-part combined Single ascending dose (SAD) and Multiple ascending dose (MAD) First-in-Human (FIH) study to investigate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of subcutaneous (SC) VIS171 in healthy participants (Part A - SAD) and in participants with autoimmune inflammatory disease(s) (Part B - MAD). Part A: Part A is a randomized, double-blind, placebo controlled SAD assessment of SC VIS171 in healthy participants. Up to 5 cohorts are planned, each comprising 8 participants (6 VIS171 and 2 placebo). Part B: Part B is an open-label, MAD basket assessment of SC VIS171 in participants with autoimmune inflammatory disease(s). Two to 3 cohorts are planned, each comprising 12 participants.


Recruitment information / eligibility

Status Terminated
Enrollment 61
Est. completion date February 15, 2024
Est. primary completion date February 15, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: Inclusion criteria for both Part A and Part B: - Male or female participant between 18 and 55 years of age, inclusive, at the screening visit (Part A and Part B [participants with selected autoimmune diseases]) or between 18 and 75 years of age, inclusive, at the screening visit (Part B [participants with specific autoimmune disease]). - Body mass index between 17 and 35 kg/m^2. - Female participants will be nonpregnant, nonlactating, and either postmenopausal for at least 2 years or surgically sterile for at least 3 months. - Male participants with female partners of childbearing potential must agree to use double barrier contraception or abstain from sex during the study and until 90 days following the last dose of study intervention. Additional inclusion criterion for Part A: - Healthy, as determined by prestudy medical evaluation (medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations). Additional inclusion criteria for Part B (participants with specific autoimmune disease[s]): - Diagnosis of a specified autoimmune disease based on standard criteria for the condition. - Other criteria may apply depending on the autoimmune condition. Exclusion Criteria: Exclusion criteria for both Part A and Part B: Prior and Concomitant Therapy - Receipt of high dose corticosteroid therapy within 4 weeks prior to screening. - Receipt of belimumab within 6 months prior to screening. - History of treatment with rituximab or ocrelizumab (or other B cell-depleting agent) within 12 months prior to screening. - History of cytotoxic medications within the preceding 12 months. - Receipt of blood products within 6 months prior to screening. Prior/Concurrent Clinical Study Experience: - Receipt of any investigational product within 4 weeks or 5 half-lives of the respective product prior to signing of the ICF, whichever is greater. - Currently participating in another clinical study of any investigational drug, device, or intervention. Diagnostic Assessments - Participants with uncontrolled hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg in any position) or symptomatic hypotension. - Any chronic infectious disease. - Participant with a positive urine drug or alcohol breath screen test result at screening. Other Exclusions: - Any participant who has a history of alcohol or drug/chemical abuse. - Participant who has donated > 500 mL of blood within 60 days prior to the start of screening or any plasma within 7 days prior to baseline (Day -1). - History of opportunistic infection requiring hospitalization or intravenous (IV) antimicrobial treatment within 1 year prior to randomization. - History of major surgery within 12 weeks of screening or will require major surgery during the study. - Clinically significant electrocardiographic abnormalities, at screening. - A QT interval corrected for heart rate using Fridericia's correction (QTcF) > 450 msec for male participants or > 470 msec for female participants at screening. - Participant has received an organ transplant. - History of any significant cardiovascular disease or thrombotic episode. - History of cancer, apart from: squamous or basal cell carcinoma of the skin that has been successfully treated; cervical cancer in situ that has been successfully treated. - Coronavirus Disease 2019 (COVID-19): current symptoms of infection; diagnosis of COVID-19 in the 21 days prior to Screening; ongoing diagnosis of "Long-COVID" symptoms. - Received a vaccination, other than COVID-19 vaccination, during the 30 days prior to administration of the first dose of study intervention. A COVID-19 vaccination cannot be received within 7 days prior to the first dose of study intervention and until 14 days after the last dose. Additional exclusion criteria for Part A: Medical Conditions - Participant has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, blood dyscrasias or other medical disorder, including psychiatric disorders, cirrhosis, or malignancy. - Participant has a history or presence of proteinuria, chronic kidney disease, disease requiring immunosuppressive therapy (including systemic steroids), or is considered to be immunosuppressed for any other reason. - History of a previous severe allergic reaction with generalized urticaria; angioedema or anaphylaxis. - Known immunodeficiency disorder. - History of chronic infection or any infection requiring hospitalization or treatment with antivirals, antibiotics, or antifungal therapy within 30 days prior to administration of the study intervention. - Alanine transaminase (ALT) or aspartate transaminase (AST) > 1.5 × the upper limit of normal (ULN). - Total bilirubin > 1.5 × ULN (isolated bilirubin > 1.5 × ULN is acceptable if total bilirubin is fractionated and direct bilirubin < 35%). - Known hepatic or biliary abnormalities. Additional exclusion criterion for Part A and Part B (participants with participants with specific autoimmune disease may apply depending upon the autoimmune condition).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
VIS171
Participants will receive VIS171 via SC route of administration.
Placebo
Participants will receive Placebo via SC route of administration

Locations

Country Name City State
Bulgaria UMHAT Plovdiv
Bulgaria Ambulatory for Specialized Medical Help - skin and venereal diseases Sofia
Bulgaria Comac Medical Ltd Sofia
Bulgaria Diagnostic and Consultative Center Convex EOOD Sofia
Bulgaria MBAL Sveta Sofia Sofia
Germany Universitaetsklinikum Bonn AöR Bonn
Germany Universitätsmedizin der Johannes-Gutenberg-Universität Mainz Rheinland-Pfalz
Moldova, Republic of Clinical republican Hospital Chisinau
Netherlands Radboud University Medical Center Gelderland
New Zealand New Zealand Clinical Research Christchurch

Sponsors (1)

Lead Sponsor Collaborator
Visterra, Inc.

Countries where clinical trial is conducted

Bulgaria,  Germany,  Moldova, Republic of,  Netherlands,  New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part A and Part B: Numbers of participants with treatment-emergent adverse events (TEAEs) Part A: From screening up to Day 29; Part B: From screening up to Day 71
Secondary Part A and Part B: Mean change from baseline in absolute number (cells/µL) for Treg, helper T cells, cytotoxic T cells and natural killer cells Part A: From baseline up to Day 29; Part B: From baseline up to Day 71
Secondary Part A and Part B: Mean change from baseline in percentage for Treg, helper T cells, cytotoxic T cells and natural killer cells Part A: From baseline up to Day 29; Part B: From baseline up to Day 71
Secondary Part A and Part B: Maximum (peak) plasma VIS171 concentration (Cmax) over time Part A: From baseline up to Day 29; Part B: From baseline up to Day 71
Secondary Part A and Part B: Time of maximum (peak) plasma VIS171 concentration (tmax) Part A: From baseline up to Day 29; Part B: From baseline up to Day 71
Secondary Part A: Area under the concentration-time curve from time zero to the last observable concentration (AUClast) of VIS171 Part A: From baseline up to Day 29
Secondary Part A: Area under the concentration-time curve from time zero to infinity (AUC8) for VIS171 concentration Part A: From baseline up to Day 29
Secondary Part B: Area under the concentration-time curve over the dosing interval at steady-state (AUCtau) Part B: From baseline up to Day 71
Secondary Part A and Part B: Number of participants with Anti-drug antibodies (ADA) positive for VIS171 Part A: Day 1, 15, and 29; Part B: Day 1, 15, 29, 43, and 71
See also
  Status Clinical Trial Phase
Recruiting NCT04078698 - Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A
Recruiting NCT05670301 - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases N/A
Completed NCT03266172 - A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses Phase 1
Completed NCT03649412 - A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772 Phase 1
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Completed NCT00975936 - Phase 0 Microdose Study Phase 1
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Completed NCT01210716 - Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device Phase 3
Completed NCT00820469 - Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab Phase 4
Completed NCT01953523 - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions N/A
Withdrawn NCT03239600 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS) Phase 2
Completed NCT04872257 - Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo N/A
Recruiting NCT06019611 - Epidural Stimulation in Multiple Sclerosis N/A
Recruiting NCT05030779 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus Early Phase 1
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT04005456 - Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design N/A
Recruiting NCT05085444 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma Early Phase 1
Recruiting NCT05853835 - First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641 Phase 1